HemaSphere (Aug 2023)
S122: MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.
- Mariam Hakobyan,
- Jens Langstein,
- Emely Kleinert,
- Maximilian Schönung,
- Mark Hartmann,
- Hannah Rohdjess,
- Sina Staeble,
- Rainer Claus,
- Lars Bullinger,
- Christopher Oakes,
- Karsten Rippe,
- Stefan Fröhling,
- Stefan Pusch,
- Christoph Plass,
- Michael Milsom,
- Daniel B. Lipka
Affiliations
- Mariam Hakobyan
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Jens Langstein
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Emely Kleinert
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Maximilian Schönung
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Mark Hartmann
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Hannah Rohdjess
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Sina Staeble
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- Rainer Claus
- 3 University of Augsburg, Personalized Tumor Medicine and Molecular Oncology, Faculty of Medicine, Augsburg, Germany
- Lars Bullinger
- 4 Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany
- Christopher Oakes
- 5 The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, United States
- Karsten Rippe
- 6 German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany, Division of Chromatin Networks, Heidelberg, Germany
- Stefan Fröhling
- 7 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Division of Translational Medical Oncology, Heidelberg, Germany
- Stefan Pusch
- 8 Heidelberg University Hospital, Department of Neuropathology, Heidelberg, Germany
- Christoph Plass
- 10 German Cancer Research center, Division of Cancer Epigenomics, Heidelberg
- Michael Milsom
- 11 German Cancer Research center, Division of Experimental Hematology, Heidelberg, Germany
- Daniel B. Lipka
- 1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany
- DOI
- https://doi.org/10.1097/01.HS9.0000967400.33954.24
- Journal volume & issue
-
Vol. 7
p. e3395424
Abstract
No abstracts available.